Changes in therapeutic strategy in metastatic castration resistant prostate cancer (mCRPC) between 2012 and 2014 from the French nationwide claims database (SNDS)

Changes in therapeutic strategy in metastatic castration resistant prostate cancer (mCRPC) between 2012 and 2014 from the French nationwide claims database (SNDS)

Bibliographic Details
Main Authors:	N. Thurin, M. Rouyer, J. Jové, M. Gross-Goupil, T. Haaser, X. Rebillard, M. Soulié, G. De Pouvourville, C. Capone, M. Pierres, S. Lamarque, E. Bignon, C. Droz-Perroteau, N. Moore, P. Blin
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320331839

Similar Items

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)

Management of elderly mCRPC patients
by: Seiichiro Ozono
Published: (2015-12-01)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Melissa Gamat-Huber, et al.
Published: (2020-09-01)

Pembrolizumab (pembro) for docetaxel-pretreated metastatic Castration-Resistant Prostate Cancer (mCRPC): Update on KEYNOTE-199, cohorts 1-3
by: J.M. Piulats, et al.
Published: (2020-07-01)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
by: H. Taghizadeh, et al.
Published: (2019-11-01)

Clinical case long-term care of the patient with mCRPC
by: I N Zaborskiy, et al.
Published: (2014-12-01)

A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISE
by: H. Payne, et al.
Published: (2020-07-01)

Withdrawal syndrome and PSA flare in the management of mCRPC with abiraterone
by: Po Hui Chiang
Published: (2015-12-01)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
by: Rebeca Lozano, et al.
Published: (2021-05-01)

Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points
by: Fred Saad, et al.
Published: (2015-05-01)

Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISE
by: D. Mott, et al.
Published: (2020-07-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-03-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-01-01)

Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis
by: Tobias Engel Ayer Botrel, et al.
Published: (2012-12-01)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
by: Nicolas Delanoy, et al.
Published: (2021-03-01)

KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)
by: R. McDermott, et al.
Published: (2020-07-01)

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
by: Arnulf Stenzl, et al.
Published: (2020-11-01)

The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study
by: Rosa Sciuto, et al.
Published: (2021-09-01)

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
by: J.M. Piulats, et al.
Published: (2020-07-01)

Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: S. Feyerabend, et al.
Published: (2020-07-01)

Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)
by: Joshi, Jay
Published: (2020)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients With mCRPC Treated With Abiraterone
by: Cristian Lolli, et al.
Published: (2016-10-01)

The Many Faces Of mCRPC- Assessing Patient Profiles and Tailoring Treatment in a Changing Landscape
by: Manfred Wirth, et al.
Published: (2014-05-01)

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
by: Ellen Wargowski, et al.
Published: (2018-03-01)

Potential prognostic value of miR-132 and miR-212 expression in mCRPC patients
by: Mariano Pontico, et al.
Published: (2021-10-01)

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
by: Maria Luisa Belli, et al.
Published: (2020-11-01)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
by: Renee N Donahue, et al.
Published: (2021-03-01)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
by: G. Gravis, et al.
Published: (2020-07-01)

The molecular pathology of Castrate Resistant Prostate Cancer (CRPC)
by: Paul Mainwaring
Published: (2015-12-01)

343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)
by: Ben Li, et al.
Published: (2020-11-01)

345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)
by: Lu Xu, et al.
Published: (2020-11-01)

Very Early PSA Response to Abiraterone in mCRPC Patients: a Novel Prognostic Factor Predicting Overall Survival
by: Gaetano eFacchini, et al.
Published: (2016-05-01)

Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling
by: Xiong Zhang, et al.
Published: (2021-04-01)

Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC)
by: L.C.V. Thomsen, et al.
Published: (2020-07-01)

341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)
by: Lawrence Karsh, et al.
Published: (2020-11-01)

An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients [version 1; referees: 1 approved, 2 approved with reservations]
by: Richard Meier, et al.
Published: (2016-11-01)

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study
by: Martin Boegemann, et al.
Published: (2019-01-01)

Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
by: Eline L. Hooijman, et al.
Published: (2021-05-01)

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
by: Andrew D. Simmons, et al.
Published: (2020-03-01)